Lazard Asset Management LLC Purchases 30,621 Shares of Pediatrix Medical Group, Inc. $MD

Lazard Asset Management LLC boosted its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 22.1% in the 1st quarter, Holdings Channel.com reports. The fund owned 168,979 shares of the company’s stock after purchasing an additional 30,621 shares during the period. Lazard Asset Management LLC’s holdings in Pediatrix Medical Group were worth $3,614,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Keybank National Association OH lifted its stake in Pediatrix Medical Group by 2.0% in the 1st quarter. Keybank National Association OH now owns 22,941 shares of the company’s stock worth $491,000 after purchasing an additional 458 shares in the last quarter. Gotham Asset Management LLC boosted its holdings in Pediatrix Medical Group by 0.6% in the 3rd quarter. Gotham Asset Management LLC now owns 116,093 shares of the company’s stock valued at $1,945,000 after purchasing an additional 724 shares during the period. ProShare Advisors LLC boosted its holdings in Pediatrix Medical Group by 4.6% in the 4th quarter. ProShare Advisors LLC now owns 16,816 shares of the company’s stock valued at $360,000 after purchasing an additional 734 shares during the period. Verition Fund Management LLC grew its position in shares of Pediatrix Medical Group by 4.4% during the 3rd quarter. Verition Fund Management LLC now owns 25,408 shares of the company’s stock valued at $426,000 after purchasing an additional 1,066 shares in the last quarter. Finally, EP Wealth Advisors LLC grew its position in shares of Pediatrix Medical Group by 5.5% during the 2nd quarter. EP Wealth Advisors LLC now owns 22,579 shares of the company’s stock valued at $324,000 after purchasing an additional 1,180 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $26.48 on Friday. The company’s fifty day moving average price is $24.60 and its 200-day moving average price is $22.49. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of 12.86 and a beta of 0.66. Pediatrix Medical Group, Inc. has a one year low of $11.84 and a one year high of $27.94. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The firm had revenue of $476.20 million for the quarter, compared to analysts’ expectations of $465.83 million. During the same quarter last year, the company posted $0.33 EPS. The business’s quarterly revenue was up 3.9% on a year-over-year basis. On average, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 2.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MD. Truist Financial upped their price target on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. UBS Group lifted their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Mizuho set a $24.00 target price on Pediatrix Medical Group in a research report on Friday, May 8th. Jefferies Financial Group restated a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $23.33.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.